Receive consulting resources in your inbox

Sheridan Capital Partners: Investment Strategy, Funds, Portfolio Companies, and Firm Profile

1. What Is Sheridan Capital Partners?

Sheridan Capital Partners is a Chicago-based private equity firm focused exclusively on healthcare. The firm reports 2012 as its founding year and targets lower-middle-market businesses in the United States and Canada. Its investment model combines control-oriented transactions, growth capital, operational support, and acquisitions that expand a platform company’s capabilities or scale.

Current firm biographies identify Jonathan B. Lewis and Sean M. Dempsey as co-founders and partners. Historical accounts of the original founding team require qualification, as explained below. Sheridan now operates a broad healthcare investment strategy alongside a dedicated healthcare information technology fund.

For this directory, its principal classification is direct private equity and buyouts, with additional descriptors of sector-specialist private equity and lower-middle-market investing. North America is the appropriate geography group, specifically reflecting its published U.S. and Canadian company criteria rather than an unrestricted continental mandate. These are editorial classifications based on the documented investment model.

2. Sheridan Capital Partners at a Glance

Firm name
Sheridan Capital Partners.
Firm type
Healthcare-focused direct private equity firm.
Founded
2012, the firm-reported founding year.
Founder or founders
Current biographies identify Jonathan B. Lewis and Sean M. Dempsey as co-founders; historical founding accounts also identify Michael Allietta.
Headquarters
Chicago, Illinois, United States; an additional office is listed in New York.
Parent organization
A current parent organization has not been verified. Historical affiliation with the Richard Stephenson Family Office does not establish present ownership.
Main investment markets
United States and Canada.
Geography group
North America.
Directory segments
Direct private equity / buyouts; sector-specialist private equity; lower-middle-market investors.
Principal strategies
Healthcare control investments and growth-oriented recapitalizations; healthcare software and technology investing.
Ownership preference
Control positions, including partial recapitalizations that can preserve founder ownership.
Typical company profile
Founder-owned, growth-oriented businesses with established demand and opportunities to build organizational scale.
Sector focus
Healthcare outsourced services, patient services, products and manufacturing, and software and technology.
Current major funds
Fund IV and Healthcare IT Fund I; Fund III remains associated with identified portfolio platforms.
Current status
Operating investment firm, with completed fund closes announced in October 2026.
Official website
Sheridan Capital Partners Official Website

3. Who Founded Sheridan Capital Partners, and How Is the Firm Organized?

Sheridan’s current biographies identify Jonathan Lewis and Sean Dempsey as co-founders and partners. Lewis previously invested at PNC Equity Partners, William Blair Capital Partners, and Lake Capital. Dempsey previously worked at Kinderhook Industries and Glenview Capital Management, after beginning his career in healthcare investment banking at Credit Suisse First Boston.

The original founding account is not fully consistent across public records. A July 2026 institutional-investor summary identifies Lewis and Michael Allietta as the 2012 founders of the general partner and describes an affiliation with the Richard Stephenson Family Office. Sheridan’s January 2013 announcement also identifies Lewis and Allietta as the partners leading its Diamondback Drugs investment. A separate Allietta biography refers to a 2011 launch. This profile uses Sheridan’s stated 2012 founding year without assuming that launch, incorporation, and the present leadership structure are identical events.

Chicago was the documented early operating base. Today, the organization distinguishes investment, business development, Acceleration Team, and fund operations functions. David Baker leads the Acceleration Team as Head of Operations. These firm resources are separate from the executives employed by individual portfolio companies.

The historical family-office affiliation should not be presented as verified current parentage. This profile covers Sheridan’s investment business and identifiable funds, not a broader family-office group or the operating businesses owned by its funds.

4. What Is the History of Sheridan Capital Partners?

Sheridan’s development is best understood through changes in its investment activity, institutional fund base, and operating organization, rather than through a single firm-size statistic.

  1. 2012 to 2013: Establishment and an early healthcare platform. Sheridan reports a 2012 founding. Its portfolio records identify the Diamondback Drugs investment in December 2012, while the January 7, 2013 announcement confirms completion of a leveraged buyout. The business supplied compounded veterinary medicines, illustrating an early focus on specialized healthcare products and services rather than only conventional medical practices.
  2. 2015: Expansion into orthodontic practice support. Sheridan partnered with Smile Doctors during 2015. Its historical case study describes an acquisition-led expansion program and continued minority involvement for several years after a recapitalization. That history illustrates why a control-investment realization and a complete firm-level exit must be distinguished.
  3. 2021: A larger institutional buyout fund. The January 19, 2021 Fund II close announcement confirmed $300 million in limited partner commitments. The vehicle continued a strategy of control investments in founder-owned North American healthcare businesses.
  4. 2023: Fund III. Sheridan announced Fund III’s final close on July 13, 2023, with $575 million in total capital commitments. Its stated investment profile remained lower-middle-market healthcare, including founder-owned companies.
  5. 2025: Broader platforms and operating resources. Sheridan completed investments in financial software, behavioral health software, and life-sciences contract manufacturing. It also added senior operating personnel. Majority sales of DAS Health and Tarrytown preserved minority ownership rather than ending all exposure.
  6. 2026: Two distinct fund channels. October brought the final closes of Fund IV and Healthcare IT Fund I. The announcement separately identified investments associated with Fund III and the specialist IT fund.

5. What Investment Strategies Does Sheridan Capital Partners Pursue?

Sheridan’s central strategy is to acquire control positions in healthcare businesses and support their development into larger, more institutionalized organizations. Its published transaction menu includes buyouts and partial recapitalizations. The latter can provide liquidity and investment capital while leaving founders or managers with continuing equity ownership. Growth is therefore an operating objective and transaction rationale, not evidence that every investment is a minority growth-equity deal.

The firm describes a thematic sourcing process: research a healthcare niche, form an investment thesis, and identify businesses within that niche. Its stated company preferences include established growth and profitability, durable demand, recurring or re-occurring revenue, fragmented markets, and limited regulatory risk. These are investment preferences, not guarantees about a company’s revenue stability or regulatory exposure.

Two complementary approaches are now visible:

  • Healthcare services and products: Platforms in outsourced services, patient services, manufacturing, distribution, and related healthcare activities, with expansion supported through operating improvements and acquisitions.
  • Healthcare software and technology: Businesses serving providers, payors, pharmaceutical organizations, patients, and employer-benefits functions, using a different published scale profile from the services and products strategy.

Acquisitions are a documented component of the model, but Sheridan also describes organic expansion into adjacent products, services, and markets. Analytically, the proposition is to combine capital with the management capacity, systems, and integration support needed to scale. It should not be reduced to either acquisition volume alone or financial restructuring alone.

6. What Funds Does Sheridan Capital Partners Manage?

Sheridan’s publicly identifiable fund structure includes successive broad healthcare funds and a separately identified healthcare IT vehicle. The manager, the individual partnerships, and the companies in which those partnerships invest are distinct entities.

  • First fund: A January 2021 account of Sheridan’s fundraising history reported that its first fund closed in 2012 with $150 million in limited partner commitments. This is a historical fundraising figure, not a current asset value.
  • Sheridan Capital Partners Fund II, L.P.: The January 19, 2021 final-close announcement confirmed $300 million in limited partner commitments and included a parallel fund within its definition of Fund II.
  • Sheridan Capital Partners Fund III, L.P.: The July 13, 2023 final-close announcement reported $575 million in total capital commitments, also covering its parallel fund.
  • Sheridan Capital Partners Fund IV: On October 7, 2026, Sheridan announced a final close at $1.1 billion in institutional capital commitments.
  • Healthcare IT Fund I: The same announcement confirmed a close with $245 million in capital commitments.

All amounts above are U.S. dollars. The measures are not identical: Fund II’s cited amount is limited partner commitments, Fund III’s is total capital commitments, and Fund IV’s is institutional capital commitments. These figures are not presented as group AUM, invested capital, or portfolio valuations.

A July 2026 institutional summary described Fund IV with a ten-year term and three possible one-year extensions. That describes a finite-life fund structure, not permanent capital, and should not be confused with the holding period of every underlying company.

7. What Types of Companies Does Sheridan Capital Partners Invest In?

Sheridan emphasizes founder-owned and entrepreneurially led businesses that already have a viable commercial model. Its published criteria favor a history of growth and profitability, visible demand, resilient end markets, and an opportunity to build scale in a fragmented industry. The firm’s materials also identify cash-flow-positive add-on acquisitions.

The published target ranges reviewed for this profile differ by strategy:

  • Healthcare services and products: Platform EBITDA of $5 million to $25 million and target equity investments of $30 million to $150 million.
  • Healthcare software and technology: Platform revenue of $5 million to $30 million, EBITDA of $0 to $10 million, and target equity investments of $15 million to $150 million.

These are target company and equity-investment measures, not fund sizes or enterprise values. A separate July 2026 institutional summary for Fund IV identified a primary enterprise-value range of $100 million to $300 million. That vehicle-specific description should not replace the firm’s published EBITDA and equity-ticket criteria or be applied automatically to every strategy.

Documented transactions show that founder participation can continue after investment. At Carolina Components Group, founder John Cooling moved to the board while he and other company leaders remained meaningful owners. Such a structure can combine leadership succession, liquidity, and a new phase of expansion. It does not imply that Sheridan requires every founder to leave day-to-day management.

8. Which Industries Does Sheridan Capital Partners Focus On?

Healthcare is the organizing sector, but Sheridan invests across several different business models within it. A software vendor, a pharmacy, a bioprocessing supplier, and a clinical-services platform have materially different customers, operating requirements, and growth mechanisms.

Healthcare information technology is a distinct current investment area. Cadara supplies financial and billing software for post-acute facilities. ICANotes provides electronic medical record software for behavioral health organizations. PtEverywhere combines practice management, clinical documentation, and payments for physical therapy and rehabilitation providers. These are operating software businesses, not simply technology features added to a provider roll-up.

Products and manufacturing include exposure to the medical devices, diagnostics, and consumables supply chain. Currier Plastics manufactures precision plastic components for healthcare and life-sciences customers. Carolina Components Group supplies bioprocessing components and assemblies used in biopharmaceutical production. These investments concern manufacturing and supply-chain capabilities rather than ownership of drug-development programs.

Patient services remain part of the published strategy. Historical exposure includes dental service organizations through Smile Doctors. Sheridan’s stated patient-service interests also include behavioral health, women’s health, specialty veterinary services, and post-acute care; a stated interest is not proof of a current investment in every category.

Healthcare support services extend the scope further. DAS Health provides managed IT and related business solutions, Tarrytown operates a specialized long-term care pharmacy, and Tres Health supplies employer health-benefit and insurance-administration solutions supported by its technology platform.

9. Where Does Sheridan Capital Partners Invest?

Sheridan is headquartered in Chicago, in the United States. Its current contact information also lists a New York office. These are organizational locations; they should not be treated as the boundaries of its investment mandate.

The firm’s published company criteria specify headquarters in the United States or Canada. North America therefore describes the principal investment geography, with those two countries providing the more precise market definition. Both the broad healthcare and software materials use this company-headquarters criterion.

Fund-specific descriptions can be narrower. The July 2026 institutional summary for Fund IV described investments in U.S. healthcare companies. That is a description of the particular vehicle, not grounds to erase Canada from Sheridan’s broader published firm-level criteria.

Fundraising geography is another separate dimension. Fund III’s close announcement identified investors across North America, Europe, and the Middle East. Those limited partner locations do not establish a European or Middle Eastern portfolio-company mandate.

Analytically, Sheridan’s geographic model combines a U.S. organizational base with U.S. and Canadian investment criteria. Individual portfolio companies may serve customers beyond their headquarters market, but such commercial reach should not automatically be characterized as a separate regional investment strategy.

10. How Does Sheridan Capital Partners Seek to Create Value?

Sheridan describes an operating model organized around people, processes, and systems. Its stated approach includes strengthening management, adding infrastructure and reporting capabilities, supporting facility or service-line expansion, and modernizing technology. These are firm-described methods, not independently demonstrated outcomes across every portfolio company.

The Acceleration Team provides several distinct types of support:

  • Value Creation Team: Sheridan operators work with investment professionals and oversee operating resources.
  • Resident Leadership: Onsite operators augment or temporarily substitute management during important transitions.
  • Functional Resource Team: Project-level consultants provide specialized expertise.
  • Strategic and Executive Advisory Team: Industry executives support diligence, strategy, and execution through advisory and board-level roles.

Current functional leadership includes Amanda Lyle in finance, Joe Miu in human capital, Kelly Wagner in growth, and Pritesh Patel in digital and AI transformation. Wagner’s role includes sales and commercial capabilities. Patel’s appointment establishes a dedicated digital and AI resource, but does not establish quantified AI benefits or deployment at every company.

Acquisition support is visible in company-specific activity. Currier completed the acquisition of Sage Product Development in August 2026, adding medical-device engineering and development services. Sheridan’s historical Smile Doctors case describes 27 add-on acquisitions during its investment. These examples document different expansion mechanisms; neither should be treated as a standardized program applied uniformly to all holdings.

11. What Types of Business Situations May Fit Sheridan Capital Partners?

The following situations appear consistent with Sheridan’s documented strategy. They are analytical fit indicators, not eligibility rules, investment advice, or a statement of current investment appetite.

  • A founder seeking liquidity while retaining participation. Partial recapitalizations are part of Sheridan’s transaction menu. Carolina Components Group provides a documented example of founders and company leaders retaining ownership alongside the investment.
  • A business whose operating infrastructure needs to catch up with growth. Sheridan’s described resources address management capacity, finance, organizational design, systems, and reporting. Such needs are consistent with its emphasis on institutionalizing entrepreneurially led companies.
  • A platform with a credible acquisition path. Fragmented markets and cash-flow-positive add-ons feature in its published criteria. Currier’s addition of engineering capabilities illustrates acquisitions that extend services, not simply replicate existing operations.
  • An established healthcare software business. The specialist technology criteria accommodate a different revenue and EBITDA profile from the services and products strategy. PtEverywhere’s completed investment demonstrates exposure to workflow and payments software for rehabilitation providers.

Fit depends on the specific business, ownership objectives, transaction structure, and applicable fund. Sector relevance alone does not establish suitability.

12. What Distinguishes Sheridan Capital Partners?

Four documented characteristics explain Sheridan’s investment proposition without requiring claims of superior performance.

  1. Healthcare specialization across different business models. The firm’s focus encompasses services, software, manufacturing, and products. Its specialization is sector-wide, rather than limited to one type of healthcare provider.
  2. Research-led investment themes. Sheridan describes developing conviction in selected niches before targeting companies. In an April 2026 discussion, Dempsey described extended thesis-development work rather than simply accepting the first available transaction within a theme. This is the firm’s account of its sourcing process, not proof that every deal is proprietary.
  3. A layered operating-support model. The combination of internal operators, resident leadership, project specialists, and executive advisers gives more definition to “operational support” than a general promise of access to a network. Those categories remain distinct and should not all be characterized as permanent employees.
  4. Control-oriented investing with room for continuing founder ownership. Buyouts and partial recapitalizations coexist. Carolina Components Group illustrates retained founder ownership alongside a leadership transition, while Sheridan’s resources can support the next organizational phase.

Taken together, these characteristics suggest a proposition centered on sector knowledge and the practical work of scaling businesses. They do not establish better returns, lower risk, or superiority to another investor.

13. How Should Sheridan Capital Partners Be Understood Today?

As of the October 13, 2026 review cutoff, Sheridan should be understood as an operating healthcare specialist with separate broad healthcare and healthcare IT fund channels. The October closes are completed fundraising events, not targets or anticipated future closes. Their commitment amounts are reported in the funds section with the appropriate measures.

What remains central is its focus on entrepreneurially led businesses, control-oriented transactions, and operating support. What has developed is the breadth of its platform activity and the specificity of its functional resources. Current documented holdings include software, bioprocessing supplies, and contract manufacturing, while the Acceleration Team includes dedicated finance, human capital, growth, and digital transformation roles.

The portfolio must also be read at firm level rather than solely through “realized” labels. DAS Health and Tarrytown illustrate continuing minority exposure after majority transactions. Conversely, a historical case study should not be used by itself to assert present ownership.

Important limitations remain explicit: the original founding account is not fully reconciled, present parentage has not been verified, and the portfolio table is selective. Inclusion in Umbrex’s Top 1000 Global Private Equity Firms collection identifies research coverage. It is not a verified ranking, endorsement of performance, or assessment of suitability for a particular company.

14. Frequently Asked Questions

Is Sheridan Capital Partners a healthcare-only investor?

Its current materials describe an exclusive healthcare focus. That includes outsourced services, patient services, products and manufacturing, and software and technology, rather than only hospitals, clinics, or businesses directly delivering patient care.

Who founded Sheridan Capital Partners?

Current biographies identify Jonathan Lewis and Sean Dempsey as co-founders. Historical accounts also identify Michael Allietta in the original founding story. The firm reports 2012 as its founding year, but the complete original team is not fully reconciled.

Does Sheridan seek majority ownership?

Its published criteria emphasize control positions, buyouts, and partial recapitalizations. Control does not require complete ownership: founders and managers can retain equity. Sheridan can also hold minority positions after selling control of an investment.

Which funds are its newest publicly announced vehicles?

Fund IV and Healthcare IT Fund I closed in October 2026. The former is the broad healthcare flagship; the latter is a separately identified specialist IT fund. Their capital commitments should not be treated as interchangeable portfolio values.

What company sizes does Sheridan target?

Published services and products criteria identify platform EBITDA of $5 million to $25 million. Software criteria identify revenue of $5 million to $30 million and EBITDA of $0 to $10 million. These are targets, not universal eligibility requirements.

Why are DAS Health and Tarrytown listed as Current?

Sheridan retained minority ownership after their majority sales in 2025. Current therefore describes continuing firm-level equity exposure, not continued control. Treating those transactions as complete exits would obscure the retained investment relationship.

Does Sheridan invest beyond the United States?

Its firm-level company criteria include the United States and Canada. Headquarters and office locations are separate from investment geography, and the geographic distribution of fund investors does not establish additional portfolio-company markets.